Brainsway Receives FDA Approval

Brainsway Receives FDA Approval

JERUSALEM, Jan. 10, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN)
("Brainsway" or the "Company") is proud to announce that the U.S. Food and
Drug Administration ("FDA") has approved its proprietary Deep TMS device for
the treatment of depression in patients who have failed to respond to
antidepressant medications in their current episode of depression. It should
be noted that this indication for the use of Brainsway's device, as approved
by the FDA, is broad, both in general terms as it relates to depression
therapy and compared to the FDA-approved indications for the use of competing
TMS therapy.

The scope of the FDA-approved indication for the use of the Brainsway device
provides further confirmation of the safety and efficacy of the Deep TMS
technology, developed by Prof. Abraham Zangen at the U.S. National Institutes
of Health, in the treatment of depression patients and could fundamentally
alter the way in which depression is treated worldwide. Furthermore, this
approval represents a major breakthrough for the Company, inasmuch as it
grants it access to the U.S. market for depression therapy, which is valued at
tens of billions of dollars per year.

Brainsway is currently exploring various avenues for the marketing and
distribution of treatments using its Deep TMS device in the U.S. and across
the globe, including collaborations with well-known and experienced companies
in the industry.

Uzi Sofer, CEO of Brainsway, took this occasion to say, "'Give thanks to the
LORD, for he is good. For his mercy endures forever' (Psalms 136:1). We have
worked tirelessly for almost ten years to make it to this blessed day. These
are glad tidings not only for Brainsway, but also for depression patients and
their doctors. The broad scope of the FDA's clearance proves conclusively that
our device is both safe and effective. I believe this approval will boost
awareness and acceptance of Brainsway's Deep TMS technology not only in the
U.S., but the world over, as we continue to also work towards achieving
regulatory approval from healthcare authorities in Canada and other countries.
This is a very happy day for me personally and for every one of the Company's
employees who have all contributed to our achievements. I am hopeful that we
will have the wisdom to steer Brainsway onto ever-greater achievements moving
forward. CNS is a difficult and challenging field and few companies have any
projects in their pipelines in this field. We have dozens of products ready to
be released, and we hope to obtain clearance for these in the future."

Prof. Zangen commented, "This is exciting news for the world of medicine in
general and the field of psychiatric research in particular, which is ever in
pursuit of the progress which recent decades have brought other fields of
medical research. This seal of approval from the FDA is a testament to the
effectiveness of the technology that I first started to develop with Dr. Roth
more than ten years ago, and is likely to pave the way for affordable and
accessible treatment for depression all over the world."

Ronen Segal, CTO of Brainsway, commented, "This broad-scope approval clearly
demonstrates that Deep TMS is a game-changing technology in the field of
treatment for neurological and psychiatric brain disorders. Today, we have
entered a new age, in which Brainsway is standing at the helm of a global
technological revolution in the medical device industry. An industry once
primarily involved in the development of diagnostic measures now possesses the
capability to effectively treat disorders, and offers a real alternative to
treatment thus far dominated by the drug industry."

Dr. Yiftach Roth, Brainsway's Chief Scientist and one of the developers of the
Deep TMS technology, said, "The FDA's approval is great news for the Company,
of course, but more importantly, for millions of people in the U.S. and
worldwide who suffer from depression. These individuals, who have failed to
find relief for their condition using existing treatments, may finally find
therapeutic relief for their affliction. The safety and efficacy of depression
therapy with Brainsway's device have been demonstrated extensively, and
patients now have the option of receiving comfortable, noninvasive treatment
without the need for anesthesia or hospitalization, and without any
significant side effects that might affect their quality of life."

Prof. Hilik Levkovitch, Director at the Shalvata Mental Health Center, one of
the two Principal Investigators of the Clinical Trial and a pioneer of TMS in
Israel, remarked, "Brainsway's depression therapy is a breakthrough and a
credit to the clinical research efforts that have been made in order to combat
depression. This innovative treatment - developed here in Israel and now
approved by the U.S. FDA – is a great source of pride."

About Brainsway Ltd.

Brainsway develops a medical device for the noninvasive treatment of common
brain disorders. The device is based on a uniquely shaped electromagnetic coil
connected to a rapidly changing current supply, which produces magnetic fields
capable of affecting different areas of the brain. Deep brain areas can be
either excited or inhibited, depending on the frequency of the magnetic field.

CONTACT: Stephen Kilmer
         Tel: 212.618.6347
         stephen@kilmerlucas.com
 
Press spacebar to pause and continue. Press esc to stop.